Introduction {#s1}
============

Cancer is a disease resulting from complex interactions between environmental and genetic factors [@pone.0042899-Bredberg1]--[@pone.0042899-Pharoah1]. Genetic factors, including the sequence alterations and organization aberrations of the cellular genome that range from single-nucleotide substitutions to gross chromosome, could modulate several important biological progress and alert susceptibility to cancer consequently.

The transforming growth factor-β (TGF-β) signaling pathway has been the focus of extensive research since it was first discovered in 1981 [@pone.0042899-Moses1], [@pone.0042899-Roberts1]. It has now been well established that this signaling pathway is an important modulator of several biological processes, including cell proliferation, differentiation, migration and apoptosis [@pone.0042899-Gordon1]. Aberrations of the TGF-β signaling pathway are frequently found in many diseases including human cancers in breast, colon, prostate or pancreas [@pone.0042899-Benson1]--[@pone.0042899-Galliher1]. As overall TGF-β signaling may be determined by genetic polymorphisms in several TGF-β pathway genes, an increasing number of studies have pointed to the effects of TGF-β pathway gene variants on cancer risk. As the central propagator of TGF-β signaling pathway, TGF-β receptor type I (TGFBR1) has been the hot spot of research.

TGFBR1 gene locates on chromosome 9q22 [@pone.0042899-Pasche1]. Two commonly studied polymorphisms of TGFBR1 gene are TGFBR1\*6A (rs1466445), which results from the deletion of three alanines within a nine-alanine (\*9A) stretch in exon 1 [@pone.0042899-Chen1] and IVS7+24G\>A (rs334354), which represents a G to A transversion in the +24 position of the donor splice site in intron 7. Although the functional role of IVS7+24G\>A is unclear yet, TGFBR1\*6A has been suggested to be responsible for efficiency in mediating TGF-β growth inhibitory signals [@pone.0042899-Pasche2]. Therefore, it is biologically reasonable to hypothesize that polymorphisms of TGFBR1 gene may play a functional role in carcinogenesis.

A number of studies have investigated the association between TGFBR1 polymorphisms and cancer risk, but results are somewhat controversial and underpowered. For TGFBR1\*6A, a recent meta-analysis in 2010 by Liao et al. [@pone.0042899-Liao1] found significant association with overall cancer, however, several new papers are further available [@pone.0042899-Dai1]--[@pone.0042899-MartinezCanto1]. With respect to IVS7+24G\>A polymorphism, only 2 meta-analysis on this issue had ever appeared [@pone.0042899-Zhang1], [@pone.0042899-Zhang2]. Zhang [@pone.0042899-Zhang1] found the IVS7+24G\>A carriers had a 76% increase of risk of cancer (OR = 1.76, 95% CI = 1.33∼2.34) with only 440 cases and 706 controls in 3 studies. Meanwhile, Zhang et al. [@pone.0042899-Zhang2] limited the investigation on colorectal cancer and found that there was a significantly increased risk for homozygosity A/A carriers compared to heterozygosity and homozygosity of the allele G carriers (OR = 1.71, 95% CI = 1.17∼2.51). To derive a more precise estimation of the relationship between TGFBR1 polymorphisms and cancer risk, we carried out an updated meta-analysis of all available case--control studies relating the TGFBR1\*6A and/or IVS7+24G\>A polymorphisms of the TGFBR1 gene to the risk of cancer. To the best of our knowledge, this is the most comprehensive meta-analysis regarding the TGFBR1 polymorphisms and cancer risk.

![Flow diagram of study identification.](pone.0042899.g001){#pone-0042899-g001}
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###### Characteristics of case-control studies included in TGFBR1 TGFBR1\*6A polymorphism and cancer risk.
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  First author                                                             Year     Country       Ethnicity        Cancer type      Sample size   Case   Control                     
  ----------------------------------------------------------------------- ------ ------------- ---------------- ------------------ ------------- ------ --------- ----- ------ ----- ----
  Pasche [@pone.0042899-Pasche3]                                           1999       USA           Mixed             Colon           111/732      90      17       4    654    78    0
  Pasche [@pone.0042899-Pasche3]                                           1999       USA           Mixed            Ovarian          47/732       39       7       1    654    78    0
  Pasche [@pone.0042899-Pasche3]                                           1999       USA           Mixed             Breast          152/732     128      24       0    654    78    0
  Pasche [@pone.0042899-Pasche3]                                           1999       USA           Mixed        Germ cell cancer     56/732       49       5       2    654    78    0
  Pasche [@pone.0042899-Pasche3]                                           1999       USA           Mixed              Lung           94/732       82      11       1    654    78    0
  Pasche [@pone.0042899-Pasche3]                                           1999       USA           Mixed            Prostate         59/732       51       8       0    654    78    0
  Pasche [@pone.0042899-Pasche3]                                           1999       USA           Mixed            Pancreas         14/732       12       2       0    654    78    0
  Pasche [@pone.0042899-Pasche3]                                           1999       USA           Mixed            Bladder          77/732       67      10       0    654    78    0
  Pasche [@pone.0042899-Pasche3] [a](#nt101){ref-type="table-fn"}          1999       USA           Mixed          Hematologic        228/732     189      38       1    654    78    0
  Pasche [@pone.0042899-Pasche3]                                           1999       USA           Mixed            Melanoma         10/732       9        1       0    654    78    0
  Pasche [@pone.0042899-Pasche3]                                           1999      Italy        Caucasian           Breast           48/50       39       8       1     38    12    0
  Pasche [@pone.0042899-Pasche3]                                           1999      Italy        Caucasian          Bladder          234/50      199      35       0     38    12    0
  Pasche [@pone.0042899-Pasche3]                                           1999      Italy        Caucasian           Colon            65/50       57       8       0     38    12    0
  Chen [@pone.0042899-Chen2]                                               1999       USA             NS             Cervical          37/38       29       7       1     34     4    0
  Chen [@pone.0042899-Chen2]                                               1999     Jamaica        African           Cervical          29/30       26       3       0     27     3    0
  van Tilborg [@pone.0042899-vanTilborg1]                                  2001   Netherlands     Caucasian          Bladder          146/183     121      25       0    148    32    3
  Stefanovska [@pone.0042899-Stefanovska1]                                 2001    Macedonia      Caucasian         Colorectal        117/200     108       8       1    179    20    1
  Samowitz [@pone.0042899-Samowitz1]                                       2001       USA           Mixed             Colon           250/358     202      46       2    295    58    5
  Baxter [@pone.0042899-Baxter1]                                           2002       UK          Caucasian           Breast          355/248     268      83       4    207    39    2
  Baxter [@pone.0042899-Baxter1]                                           2002       UK          Caucasian          Ovarian          304/248     236      62       6    207    39    2
  Chen [@pone.0042899-Chen1]                                               2004       USA           Mixed             Renal           88/138       71      15       2    112    25    1
  Chen [@pone.0042899-Chen1]                                               2004       USA           Mixed            Bladder          63/138       49      13       1    112    25    1
  Kaklamani [@pone.0042899-Kaklamani1]                                     2004       USA           Mixed            Prostate         442/465     380      59       3    402    62    1
  Reiss [@pone.0042899-Pasche4]                                            2004       USA           Mixed             Breast           98/91       87      11       0     77    14    0
  Ellis [@pone.0042899-Pasche4]                                            2004       USA       Ashkenazi Jews        Colon           767/766     655      108      4    663    100   3
  Caldes [@pone.0042899-Pasche4]                                           2004      Spain        Caucasian           Breast          271/292     214      56       1    250    42    0
  Caldes [@pone.0042899-Pasche4]                                           2004      Spain        Caucasian         Colorectal        235/292     183      50       2    250    42    0
  Offit [@pone.0042899-Pasche4]                                            2004       USA             NS              Breast          462/330     391      67       4    291    38    1
  Northwestern [@pone.0042899-Pasche4]                                     2004       USA             NS         Breast, Ovarian      86/123       74      12       0    105    17    1
  Northwestern [@pone.0042899-Pasche4]                                     2004       USA             NS              Colon           35/123       30       5       0    105    17    1
  Jin [@pone.0042899-Jin1]                                                 2004     Finland       Caucasian           Breast          221/234     177      38       6    171    60    3
  Jin [@pone.0042899-Jin1]                                                 2004     Poland        Caucasian           Breast          170/202     140      28       2    176    26    0
  Suarez [@pone.0042899-Suarez1]                                           2005       USA           Mixed            Prostate         534/488     441      87       6    407    79    2
  Spillman [@pone.0042899-Spillman1]                                       2005       USA           Mixed            Ovarian          578/607     468      100     10    497    104   6
  Kaklamani [@pone.0042899-Kaklamani2]                                     2005       USA           Mixed             Breast          611/690     515      92       4    612    77    1
  Chen [@pone.0042899-Chen3]                                               2006       USA           Mixed             Breast          115/130      92      23       0    111    18    1
  Feigelson [@pone.0042899-Feigelson1] [b](#nt102){ref-type="table-fn"}    2006       USA           Mixed             Breast          481/484     387      94      384   100         
  You [@pone.0042899-You1]                                                 2007      China          Asian              Lung           252/250     217      35       0    219    31    0
  Cox [@pone.0042899-Cox1]                                                 2007       USA             NS              Breast         1187/1673    968      207     12    1352   302   19
  Song [@pone.0042899-Song1]                                               2007     Sweden        Caucasian           Breast          763/852     598      152     13    682    160   10
  Skoglund [@pone.0042899-Skoglund1]                                       2007     Sweden        Caucasian         Colorectal       1040/852     827      203     10    682    160   10
  Skoglund Lundin [@pone.0042899-SkoglundLundin1]                          2009     Sweden        Caucasian         Colorectal        213/852     167      42       4    682    160   10
  Castillejo [@pone.0042899-Castillejo1]                                   2009      Spain        Caucasian          Bladder         1094/1014    887      199      8    812    191   11
  Jakubowska [@pone.0042899-Jakubowska1]                                   2010     Poland        Caucasian           Breast          318/290     282      33       3    252    38    0
  Jakubowska [@pone.0042899-Jakubowska1]                                   2010     Poland        Caucasian          Ovarian          144/279     122      22       0    244    35    0
  Colleran [@pone.0042899-Colleran1]                                       2009     Ireland       Caucasian           Breast          960/958     796      154     10    785    160   13
  Dai [@pone.0042899-Dai1]                                                 2009     German        Caucasian            ALL            458/552     390      61       7    456    88    8
  Carvajal-Carmona [@pone.0042899-CarvajalCarmona1]                        2010       UK          Caucasian         Colorectal        913/828     746      159      8    673    145   10
  Carvajal-Carmona [@pone.0042899-CarvajalCarmona1]                        2010       UK          Caucasian         Colorectal        933/990     772      152      9    843    140   7
  Carvajal-Carmona [@pone.0042899-CarvajalCarmona1]                        2010       UK          Caucasian         Colorectal       1152/1333    938      201     13    1119   200   14
  Forsti [@pone.0042899-Forsti1]                                           2010     Sweden        Caucasian         Colorectal        293/558     218      69       6    435    115   8
  Hu [@pone.0042899-Hu1]                                                   2010      China          Asian          Osteosarcoma       168/168     107      51      10    134    31    3
  Abuli [@pone.0042899-Abuli1]                                             2011      Spain        Caucasian         Colorectal        509/513     427      78       4    405    103   5
  Dong [@pone.0042899-Dong1]                                               2011      China          Asian           Esophageal        482/584     409      69       4    499    79    6
  Guo [@pone.0042899-Guo1]                                                 2011      China          Asian            Gastric          468/584     393      70       5    499    79    6
  Joshi [@pone.0042899-Joshi1]                                             2011      India          Asian             Breast          167/222     163       4       0    213     9    0
  Joshi [@pone.0042899-Joshi1]                                             2011      India          Asian             Breast          42/169       33       8       1    148    19    2
  Martinez-Canto [@pone.0042899-MartinezCanto1]                            2012      Spain        Caucasian         Colorectal        521/404     442      72       7    334    67    3

The combination of Leukemia, lymphoma and MM (multiple myeloma).

This study was excluded from the combined allelic effect and recessive model because of insufficient data on the frequencies of 9A/6A and 6A/6A genotype.

NS: not stated, ALL: acute lymphocytic leukemia.

10.1371/journal.pone.0042899.t002

###### Characteristics of case-control studies included in TGFBR1 IVS7+24G\>A polymorphism and cancer risk.
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  First author                              Year       Country        Ethnicity   Cancer type    Sample size   Case   Control                    
  ---------------------------------------- ------ ------------------ ----------- -------------- ------------- ------ --------- ----- ----- ----- -----
  Chen [@pone.0042899-Chen2]                1999   USA, Netherlands     Mixed       Cervical        16/38       9        7       0    24    12     2
  Chen [@pone.0042899-Chen1]                2004         USA            Mixed        Renal         86/113       46      36       4    81    32     0
  Chen [@pone.0042899-Chen1]                2004         USA            Mixed       Bladder        65/113       33      28       4    81    32     0
  Chen [@pone.0042899-Chen1]                2006         USA            Mixed        Breast        223/153     120      92      11    113   37     3
  Song [@pone.0042899-Song1]                2007        Sweden        Caucasian      Breast        767/853     500      238     267   559   265   29
  Castillejo [@pone.0042899-Castillejo2]    2009        Spain         Caucasian    Colorectal      504/504     296      178     30    333   156   15
  Lundin [@pone.0042899-SkoglundLundin1]    2009        Sweden        Caucasian    Colorectal      262/856     135      67      12    559   265   29
  Zhang [@pone.0042899-Zhang3]              2009        China           Asian      Colorectal      206/838      60      103     43    245   431   162
  Dai [@pone.0042899-Dai1]                  2009        German        Caucasian       ALL          456/551     285      147     24    356   170   25
  Forsti [@pone.0042899-Forsti1]            2010        Sweden        Caucasian    Colorectal      308/585     220      68      14    382   179   20
  Dong [@pone.0042899-Dong1]                2011        China           Asian      Esophageal      482/584     296      163     23    402   168   14
  Guo [@pone.0042899-Guo1]                  2011        China           Asian       Gastric        468/584     291      155     22    402   168   14
  Hu [@pone.0042899-Hu2]                    2011        China           Asian     Osteosarcoma     168/168     100      57      11    115   48     5

Materials and Methods {#s2}
=====================

Identification and Eligibility of Relevant Studies {#s2a}
--------------------------------------------------

This study was performed according to the proposal of Meta-analysis of Observational Studies in Epidemiology group (MOOSE) [@pone.0042899-Stroup1]. A systematic literature search was performed for articles regarding TGFBR1 SNPs associated with cancer risk. The MEDLINE, Embase, and Chinese National Knowledge Infrastructure (CNKI) were used simultaneously, with the combination of terms "TGFBR1 or transforming growth factor receptor 1 or Type I TGF-beta receptor", "polymorphism or variant or SNP" and "cancer or neoplasm or carcinoma" (up to May 12, 2012). Reference lists of the identified articles were also examined and the literature retrieval was performed in duplication by two independent reviewers (Yong-qiang Wang and Xiao-wei Qi). Studies that were included in the meta-analysis had to meet all of the following criteria: (1) the publication was a case--control study referring to the association between TGFBR1 polymorphisms (TGFBR1\*6A and/or IVS7+24G\>A) and cancer, (2) the papers must offer the sample size, distribution of alleles, genotypes or other information that can help us infer the results, (3) when multiple publications reported on the same or overlapping data, we used the most recent or largest population as recommended by Little et al. [@pone.0042899-Little1], and (4) publication language was confined to English and Chinese.

10.1371/journal.pone.0042899.t003

###### Pooled analysis of association of TGFBR1 TGFBR1\*6A (rs1466445) and cancer risk.
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                                                        Dominant model          Recessive model   Additive model                                                                                      
  --------------------------- ---- ------------- ----------------------------- ----------------- ---------------- ----------------------------- ------- ------- ----------------------------- ------- -------
  **Total**                    58   19767/18516   **1.105 (1.035**∼**1.181)**        0.024            28.7%        **1.358 (1.113**∼**1.657)**   0.341   6.9%    **1.125 (1.053**∼**1.201)**   0.006   35.1%
  **Cancer tpye**                                                                                                                                                                                     
  Colorectal                   15    7154/8851        1.076 (0.956∼1.212)            0.048            41.2%            1.222 (0.887∼1.683)       0.523   0.0%        1.085 (0.963∼1.222)       0.016   49.4%
  Ovarian                      4     1071/1866        1.218 (0.983∼1.510)            0.526             0.0%        **2.296 (1.011**∼**5.218)**   0.160   45.0%   **1.246 (1.022**∼**1.520)**   0.435   0.0%
  Breast                       17    6421/7647        1.122 (0.978∼1.287)            0.023            45.2%            1.332 (0.921∼1.925)       0.753   0.0%    **1.151 (1.008**∼**1.314)**   0.034   43.1%
  Lung                         2      346/982         1.173 (0.782∼1.759)            0.861             0.0%          23.503 (0.951∼581.117)                          1.203 (0.817∼1.769)       0.697   0.0%
  Prostate                     3     1035/1685        1.073 (0.848∼1.358)            0.865             0.0%           2.892 (0.780∼10.717)       0.922   0.0%        1.105 (0.885∼1.380)       0.909   0.0%
  Bladder                      5     1461/2117        0.936 (0.780∼1.122)            0.536             0.0%            0.633 (0.281∼1.426)       0.472   0.0%        0.924 (0.781∼1.095)       0.512   0.0%
  Hematologic                  2     686/1284         1.185 (0.575∼2.440)            0.007            86.2%            1.331 (0.518∼3.423)       0.197   40.0%       1.197 (0.609∼2.353)       0.007   86.1%
  Cervical                     2       66/68          1.732 (0.619∼4.849)            0.454             0.0%           3.164 (0.125∼80.193)                           1.822 (0.682∼4.862)       0.401   0.0%
  **Ethnicity**                                                                                                                                                                                       
  Mixed                        20    4108/4183    **1.145 (1.049**∼**1.251)**        0.640             0.0%        **2.908 (1.735**∼**4.877)**   0.072   39.3%   **1.281 (1.149**∼**1.428)**   0.552   0.0%
  Caucasian                    25   11477/9980        1.037 (0.941∼1.142)            0.011            43.8%            1.159 (0.901∼1.491)       0.901   0.0%        1.045 (0.957∼1.141)       0.017   41.4%
  Others                       7     2603/2960    **1.208 (1.083**∼**1.347)**        0.668             0.0%            1.086 (0.611∼1.932)       0.876   0.0%        1.038 (0.908∼1.186)       0.529   0.0%
  Asian                        6     1579/1393        1.272 (0.951∼1.702)            0.089            47.7%            1.489 (0.767∼2.891)       0.403   0.0%        1.265 (0.946∼1.692)       0.052   54.4%
  **Publication bias test**                                                                                                                                                                           
  Begg's test                                             *P* = 0.537             *P* = 0.001      *P* = 0.518                                                                                        
  Egger's test                                            *P* = 0.256             *P* = 0.000      *P* = 0.129                                                                                        

*P* ~h~: test for heterogeneity, OR: odds ratio, CI: confidence interval, N: number of data sets.

*I^2^* : the percentage of total variation across studies that is a result of heterogeneity rather than chance.

Random-effects model was used; otherwise, fixed-effects model was used.

10.1371/journal.pone.0042899.t004

###### Pooled analysis of association of IVS7+24G\>A (rs334354) and cancer risk.

![](pone.0042899.t004){#pone-0042899-t004-4}

                                                      Dominant model          Recessive model   Additive model                                                                                       
  --------------------------- ---- ----------- ----------------------------- ----------------- ---------------- ------------------------------ ------- ------- ----------------------------- ------- -------
  **Total**                    13   4195/4383   **1.385 (1.146**∼**1.673)**        0.000            75.9%        **2.225 (1.263**∼**3.921)**    0.000   86.0%   **1.432 (1.140**∼**1.798)**   0.000   89.1%
  **Cancer type**                                                                                                                                                                                    
  Colorectal                   4    1226/2776       1.030 (0.779∼1.362)            0.016            71.0%        **1.379 (1.035**∼**1.837)**    0.354   7.7%        1.081 (0.876∼1.333)       0.025   68.0%
  Breast                       2    1228/1006   **1.989 (1.673**∼**2.365)**        0.345             0.0%        **5.959 (1.590**∼**22.331)**   0.046   74.9%   **2.536 (2.091**∼**3.076)**   0.256   22.3%
  **Ethnicity**                                                                                                                                                                                      
  Caucasian                    5    2481/2489       1.194 (0.854∼1.669)            0.000            88.2%            2.282 (0.848∼6.143)        0.000   93.2%       1.310 (0.833∼2.059)       0.000   95.5%
  Asian                        4    1324/1590   **1.296 (1.116**∼**1.505)**        0.410             0.0%        **1.578 (1.065**∼**2.337)**    0.205   34.6%   **1.267 (1.086**∼**1.478)**   0.190   37.0%
  Mixed                        4     390/304    **2.283 (1.694**∼**3.082)**        0.820             0.0%            3.481 (0.972∼12.491)       0.292   19.6%   **2.052 (1.580**∼**2.654)**   0.586   0.0%
  **Publication bias test**                                                                                                                                                                          
  Begg's test                                           *P = *1.000             *P = *0.246      *P = *0.360                                                                                         
  Egger's test                                          *P = *0.867             *P = *0.889      *P = *0.579                                                                                         

*P* ~h~: test for heterogeneity, OR: odds ratio, CI: confidence interval, N: number of data sets.

*I^2^* : the percentage of total variation across studies that is a result of heterogeneity rather than chance.

![Forest plot (random effects model) describing the association of the TGFBR1\*6A polymorphism with risk of cancer.\
The TGFBR1\*6A polymorphism was associated with increased risk of cancer in additive model. Each study is shown by the point estimate of the OR (the size of the square is proportional to the weight of each study) and 95% CI for the OR (extending lines).](pone.0042899.g002){#pone-0042899-g002}

Data Extraction {#s2b}
---------------

Two investigators (Yong-qiang Wang and Xiao-wei Qi) independently extracted the data from eligible studies selected according to the pre-specified criteria and the results were compared. Disagreements were resolved by discussion or by involving a third reviewer (Qiao-nan Guo). The following information of each study was collected: first author, reference year, name of studies, total number of cases and controls, studied polymorphisms, ethnicity of subjects, source of controls, and distribution of genotypes in case and control groups. For studies with inadequate information, authors were contacted for further support by E-mail if possible.

![Forest plot (random effects model) describing the association of the IVS7+24G\>A polymorphism with risk of cancer.\
The IVS7+24G\>A polymorphism was associated with increased cancer risk in additive model.](pone.0042899.g003){#pone-0042899-g003}

Statistical Analysis {#s2c}
--------------------

Meta-analysis was performed as described previously [@pone.0042899-Qi1], [@pone.0042899-Qi2]. Hardy-Weinberg equilibrium (HWE) in the controls for each study was calculated using goodness-of fit test (chi-square or Fisher's exact test). It was considered statistically significant when *P*\<0.05. Studies deviated from HWE were removed.

![Funnel plot analysis (recessive model of TGFBR1\*6A polymorphism) to detect publication bias.\
Each point represents an individual study for the indicated association. LogOR, natural logarithm of OR. Perpendicular line, mean effect size.](pone.0042899.g004){#pone-0042899-g004}

Crude odds ratios (ORs) with their 95% CIs were used to assess the strength of association between polymorphisms of TGFBR1 and cancer risk. The pooled ORs were performed for dominant model (1∶1+1∶2 vs. 2∶2), recessive model (1∶1 vs. 1∶2+2∶2), additive model (1 vs. 2) respectively. 1 and 2 represent the minor and the major allele respectively. Stratified analysis was also performed by ethnicity and cancer type. Leukemia, lymphoma and MM (multiple myeloma) were merged as hematologic cancer. For ethnicity classification, African, Jews and the ethnicity not stated in original study were merged as others.

Heterogeneity assumption was assessed by chi-based Q-test. The heterogeneity was considered statistically significant if *P*\<0.10 [@pone.0042899-Lau1]. With lacking of heterogeneity among studies, the pooled OR was calculated by the fixed effects model (Mantel--Haenszel) [@pone.0042899-Mantel1]. Otherwise, the random effects model (DerSimonian and Laird) was used [@pone.0042899-DerSimonian1], [@pone.0042899-DerSimonian2]. We also calculated the quantity *I* ^2^ that represents the percentage of total variation across studies that is a result of heterogeneity rather than chance. Values of less than 25% may be considered "low", values of about 50% may be considered "moderate", and values of more than 75% may be considered "high". A value of 0 (zero) indicates no observed heterogeneity, and larger values show increasing heterogeneity.

![Influence analysis of the summary odds ratio coefficients on the association between IVS7+24G\>A polymorphism and cancer risk in recessive model.\
Results were computed by omitting each study (left column) in turn. Bars, 95% confidence interval.](pone.0042899.g005){#pone-0042899-g005}

Sensitivity analysis was carried out by removing each study at a time to evaluate the stability of the results. Publication bias was analyzed by performing funnel plots qualitatively, and estimated by Begg's and Egger's test quantitatively [@pone.0042899-Begg1], [@pone.0042899-Egger1].

All statistical analysis was conducted using STATA software (version 11.0; STATA Corporation, College Station, TX). Two-sided P-values\<0.05 were considered statistically significant.

Results {#s3}
=======

Study Characteristics {#s3a}
---------------------

After comprehensive searching, a total of 186 publications were identified. We reviewed the titles, abstracts and the full texts of all retrieved articles through defined criteria as shown in [**Figure 1**](#pone-0042899-g001){ref-type="fig"}. Finally, the pool of eligible studies included 35 studies [@pone.0042899-Chen1], [@pone.0042899-Dai1]--[@pone.0042899-MartinezCanto1], [@pone.0042899-Pasche3]--[@pone.0042899-Hu2], among which 32 with 19,767 cases and 18,516 controls were for TGFBR1\*6A polymorphism and 12 with 4,195 cases and 4,383 controls for IVS7+24G\>A polymorphism. Each study in one publication was considered as a data set separately for pooling analysis. [**Table 1**](#pone-0042899-t001){ref-type="table"} and [**Table 2**](#pone-0042899-t002){ref-type="table"} list the main characteristics of these data sets about these two polymorphisms.

Quantitative Synthesis {#s3b}
----------------------

The main results of this meta-analysis and the heterogeneity test were shown in [**Table 3**](#pone-0042899-t003){ref-type="table"} and [**4**](#pone-0042899-t004){ref-type="table"}. With respect to TGFBR1\*6A polymorphism, a total of 58 data sets in 32 studies were included in this meta-analysis. Of these data sets, 25 were Caucasian, 6 were Asian, 20 were mixed population and 7 were others. Overall, significantly elevated cancer risk was found in all genetic models (dominant model: OR = 1.11, 95% CI = 1.04∼1.18; recessive model: OR = 1.36, 95% CI = 1.11∼1.66; additive model: OR = 1.13, 95% CI = 1.05∼1.20, [**Figure 2**](#pone-0042899-g002){ref-type="fig"}). The heterogeneity was significant in all genetic models except for recessive model (*P = *0.34). In the subgroup analysis stratified by ethnicity, significantly increased cancer risk was suggested among mixed ethnicity from US studies (dominant model: OR = 1.15, 95% CI = 1.05∼1.25; recessive model: OR = 1.85, 95% CI = 1.26∼2.72; additive model: OR = 1.22, 95% CI = 1.10∼1.36) but not among Caucasian or Asian population in all genetic models. In the subgroup analysis by cancer type, no significant association with cancer risk was demonstrated in overall population with colorectal, lung, prostate, bladder, hematological and cervical cancer. For ovarian cancer, significantly increased risk was observed in recessive model (OR = 2.30, 95% CI = 1.01∼5.22) and additive model (OR = 1.25, 95% CI = 1.02∼1.52). With respect to breast cancer, significantly increased risk was found only in additive model (OR = 1.15, 95% CI = 1.01∼1.31).

With respect to IVS7+24G\>A polymorphism, a total of 12 studies with 13 data sets were included. Of these data sets, 5 were European, 4 were Asian and 4 were from USA with mixed ethnicity. Similar to TGFBR1\*6A polymorphism, significantly elevated cancer risk was associated with IVS7+24G\>A in all genetic models (dominant model: OR = 1.39, 95% CI = 1.15∼1.67; recessive model: OR = 2.23, 95% CI = 1.26∼3.92; additive model: OR = 1.43, 95% CI = 1.14∼1.80, [**Figure 3**](#pone-0042899-g003){ref-type="fig"}). The heterogeneity was significant in all genetic models (*P*\<0.1). In the subgroup analysis by ethnicity, significantly increased risk was found in Asian population (dominant model: OR = 1.30, 95% CI = 1.12∼1.51; recessive model: OR = 1.58, 95% CI = 1.07∼2.34; additive model: OR = 1.27, 95% CI = 1.09∼1.48) but not in Caucasian in all genetic models. In the subgroup analysis stratified by cancer type, significantly increased risk was detected in all genetic models in breast cancer (dominant model: OR = 1.99, 95% CI = 1.67∼2.37; recessive model: OR = 5.96, 95% CI = 1.59∼22.33; additive model: OR = 2.54, 95% CI = 2.10∼3.08). With respect to colorectal cancer, significant association was found only in recessive model (OR = 1.38; 95% CI = 1.04∼1.84).

Publication Bias and Sensitivity Analysis {#s3c}
-----------------------------------------

The shapes of the funnel plots did not reveal any evidence of obvious asymmetry for TGFBR1\*6A polymorphism in all genetic models, except for recessive model ([**Figure 4**](#pone-0042899-g004){ref-type="fig"}). The Begg's and Egger's test also suggested the same results (dominant model: *P~Begg's~* = 0.54, *P~Egger's = ~*0.26; recessive model: *P~Begg's~* ~ = ~0.00 (7.13×10^−4^), *P~Egger's~* = 0.00(2.23×10^−5^); additive model: *P~Begg's~* = 0.52, *P~Egger's = ~*0.13). For IVS7+24G\>A polymorphism, publication bias was not ruled out not only through visual inspection of asymmetry in funnel plots but also through statistical evidence of the Begg's and Egger's test (dominant model: *P~Begg's~* = 1.00, *P~Egger's = ~*0.87; recessive model: *P~Begg's~* ~ = ~0.25, *P~Egger's~* = 0.89; additive model: *P~Begg's~* = 0.36, *P~Egger's = ~*0.58).

Sensitivity analysis, which was performed to assess the publication bias and the influence of each individual study on the pooled OR by sequential removal of individual studies, showed that Song's study [@pone.0042899-Song1] was far from the midcourt line for IVS7+24G\>A polymorphism in recessive model ([**Figure 5**](#pone-0042899-g005){ref-type="fig"}). However, the heterogeneity and the pooled OR were not influenced when this article was excluded (data not shown), which indicated that our results were statistically stable.

Discussion {#s4}
==========

In the present study, we explored the association between the TGFBR1\*6A and IVS7+24G\>A polymorphisms and cancer risk, involving 35 eligible case--control studies. For TGFBR1\*6A polymorphism, 19,767 cases and 18,516 controls were included. We found that individuals with the TGFBR1\*6A allele showed an increased risk of cancer. In the stratified analysis by cancer type, significantly elevated risks were more pronounced among ovarian cancer and breast cancer. However, no significant correlation of polymorphism TGFBR1\*6A with colorectal cancer was found. These findings, though including the latest publications, were consistent with a recent meta-analysis study conducted by Liao et al. [@pone.0042899-Liao1]. While according to Colleran's study [@pone.0042899-Colleran1], TGFBR1\*6A is not associated with breast cancer. This discrepancy may be due to data missing of some important studies, which was exclusively elaborated by Zhang et al. [@pone.0042899-Zhang4]. Another meta-analysis performed by Zhang et al. [@pone.0042899-Zhang2] found TGFBR1\*6A is statistically associated with an increased colorectal cancer risk in dominant model. One factor that may contribute to the differences is that we excluded Castillejo's study [@pone.0042899-Castillejo3] for HWE deviation and included two latest studies [@pone.0042899-Joshi1], [@pone.0042899-MartinezCanto1]. Moreover, a significantly increased risk was found among mixed ethnicity from US studies but not among Caucasian and Asian, and this was the first study evaluating the relation between TGFBR1 polymorphism and overall cancer risk among different populations.

With respect to IVS7+24G\>A polymorphism, a previous meta-analysis conducted by Zhang [@pone.0042899-Zhang1] with only 440 cases and 706 controls found that the IVS7+24G\>A carriers had a 76% increase of cancer risk. Another meta-analysis conducted by Zhang et al. [@pone.0042899-Zhang2] found that IVS7+24G\>A polymorphism had significant effects on colorectal cancer risk in recessive model. However, there were defects in their meta-analysis [@pone.0042899-Zhang2] for mistaking adenoma cases of Lundin's study [@pone.0042899-SkoglundLundin1] as colorectal cancer cases. For the current meta-analysis, 4,195 cases and 4,383 controls were included. Significant correlation of IVS7+24G\>A polymorphism with cancer risk was found in all genetic models. When coming to colorectal cancer, the results were in line with Zhang et al [@pone.0042899-Zhang2]. Besides, we also found strong association between IVS7+24G\>A polymorphism and breast cancer risk, indicating that potentially functional IVS7+24G\>A polymorphism may play a low penetrance role in development of breast cancer. Significant association was found in Asian but not in Caucasian, suggesting a possible role of ethnic differences in genetic backgrounds and the environment they lived in.

To some extent, limitations of this meta-analysis should be addressed. First, the sample sizes of several included studies [@pone.0042899-Chen1], [@pone.0042899-Chen2] were rather small and not adequate enough to detect the possible risk for TGFBR1 polymorphisms. Second, cancer is a complex disease with multifactorial etiology. The gene--environment and gene--gene interactions should be further evaluated. Third, haplotype association analysis is the most powerful method to explore the intrinsic effects of gene, but most of the literatures identified in our present meta-analysis were focused on the relation between the two TGFBR1 SNPs and tumor susceptibility, which made it difficult to investigate the TGFBR1 haplotype effects on carcinogenesis. Last but not least, most of US studies were mixed ethnicity, which made it hard to obtain the effects of specific ethnicity on the associations between TGFBR1 polymorphisms and cancer risk.

In summary, this meta-analysis provided evidence that the TGFBR1\*9A/6A polymorphism is associated with overall cancer susceptibility and seem to be more susceptible to ovarian and breast cancer. Meanwhile, IVS7+24G\>A polymorphism is also associated with increased overall cancer risk especially in colorectal and breast cancer. More well-designed epidemiological studies on specific ethnicity and cancer types, which were not well covered by existing studies, will be necessary to validate the findings identified in the current meta-analysis. Further studies regarding other SNPs (or haplotypes) in the TGFBR1 gene and cancer risk are also encouraged to better understand the role of TGFBR1 in carcinogenesis.
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